Real Diagnostics,LLC

Based in the US, Real Diagnostics provides innovative diagnostic testing services, specializing in urinary tract infections, sexually transmitted infections, vaginosis, and toxicology, addressing critical healthcare needs with timely solutions. Real Diagnostics, founded in 2014, is headquartered in the US and focuses on advanced diagnostic testing services. The company has pivoted towards integrating toxicology services in response to the opioid crisis. It has completed one deal as of September 23, 2025, when Salt Creek Capital and HCAP Partners acquired the company.

Details of the acquisition were not disclosed. Real Diagnostics specializes in advanced diagnostic testing services, focusing primarily on urinary tract infections (UTIs), sexually transmitted infections (STIs), vaginosis, respiratory pathogens, and toxicology. Their core product offerings include a comprehensive UTI test that detects over 30 pathogens, a 7-pathogen STI test, a robust vaginosis test, and a PCR-based respiratory test designed to identify common upper respiratory pathogens. The toxicology services provided by Real Diagnostics are notable for their rapid turnaround times, addressing critical needs in public health, particularly amidst the ongoing opioid crisis.

Real Diagnostics serves a diverse client base, including healthcare providers, hospitals, and clinical laboratories. Their products are primarily marketed within the United States, targeting healthcare professionals who require reliable and timely diagnostic solutions for patient care. Real Diagnostics generates revenue through its diagnostic testing services, which are typically transacted on a fee-for-service basis. Healthcare providers and institutions order tests for their patients, and the company charges per test performed.

The business model may involve partnerships with healthcare facilities, allowing for streamlined ordering processes and integration into patient care workflows. Specific pricing structures for individual tests are determined based on contractual agreements with clients, which may vary by volume and service level. Key products associated with the company’s revenue generation include the flagship UTI and STI tests, which are critical in addressing public health issues, and the toxicology services that support efforts to combat the opioid epidemic. Following the acquisition by Salt Creek Capital and HCAP Partners in September 2025, Real Diagnostics plans to leverage the advantages of this partnership for growth.

Specific future initiatives include the development and launch of new diagnostic tests targeted towards emerging health issues, although precise product details and release dates remain undisclosed. The company also aims to expand its market presence beyond the United States, exploring opportunities in international healthcare markets, which will be facilitated by the resources from the recent acquisition. This strategic approach is expected to enhance their service offerings and reach in the healthcare sector.